Improving the Efficacy of Cisplatin in Colon Cancer HT– 29 Cells via Combination Therapy withSelenium

 

Clinical Imaging and Case Reports

Improving the Efficacy of Cisplatin in Colon Cancer HT– 29 Cells via Combination Therapy withSelenium
Amend K

Physicians Assistant Program, University of Saint Francis, Fort Wayne, IN.

Correspondence to Author: Amend K
Abstract:
In general, cis-platinum is ineffective in treating slow-growing colon cancer. A seleno-enzyme that neutralises reactive oxygen species is glutathione peroxidase (ROS). High ROS concentrations may affect the efficacy of cisplatinum, according to research. In HT-29 colon cancer cells, the impact of selenite supplementation during cis-platinum treatment was investigated. Agarose culture enables cells to form colonies, grow in three dimensions, and independently analyse mitosis, cell viability, and ROS production. Single cells were cultivated for seven days while suspended in agarose. At day 0, cultures were either left untreated with selenite or were pretreated with it. Cultures were either given cis-platinum alone or in combination with selenite on day 4. Cell viability and mitotic activity were assessed after 7 days. ROS degradation was measured using a glutathione peroxidase test.activity. Little dosages of selenite had no impact on mitosis or cell survival. More ROS breakdown and improved cis-platinum efficacy were seen in cultures that were treated with selenite and cis-platinum. If colonies are already present, cisplatinum alone proved less efficient than the combination of cis-platinum and selenite. Moreover, cells treated with the cisplatinum and selenite combination showed enhanced ROS breakdown, indicating a connection between ROS levels and cisplatinum efficacy.
Citation:

Amend K. Improving the Efficacy of Cisplatin in Colon Cancer HT– 29 Cells via Combination Therapy withSelenium. Clinical Imaging and Case Reports 2023.